A Study to Assess the Effect on Glucose Control and Safety and Tolerability of LY2148568 In Japanese Patients with Type 2 Diabetes

Study identifier:H8O-JE-GWAV

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Dose Response Study to Assess the Effect on Glucose Control and Safety and Tolerability of LY2148568 in Japanese Patients with Type 2 Diabetes Who are Treated with Oral Antidiabetic(s) but not well Controlled

Medical condition

Type 2 Diabetes Mellitus

Phase

Phase 2

Healthy volunteers

No

Study drug

exenatide (LY2148568), Placebo

Sex

All

Actual Enrollment

153

Study type

Interventional

Age

20 Years - 75 Years

Date

Study Start Date: 01 Sept 2006
Primary Completion Date: 01 May 2007
Study Completion Date: 01 May 2007

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Jan 2015 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

Eli Lilly and Company

Inclusion and exclusion criteria